Manal Abdelmalek MD, MPH, FAASLD

Manal F. Abdelmalek, M.D., focuses on understanding risk factors for the acquisition and progression of metabolic dysfunction-associated steatotic liver disease. She also researches the discovery of new approaches to treat its progressive form, metabolic dysfunction-associated steatohepatitis, formerly known as nonalcoholic steatohepatitis.

Dr. Abdelmalek has expertise in clinical-translational research and the design and conduct of clinical trials, including investigator-initiated, industry-sponsored, and National Institutes of Health-funded clinical studies. The research, trials, and clinical studies she undertakes evaluate new therapies and biomarkers for metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis. She collaborates extensively to transition new compounds to first-in-human clinical studies and is a leading investigator in global trials of new and emerging therapies for the treatment of metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis.

Dr. Abdelmalek is a key opinion leader in the field of metabolic dysfunction-associated steatohepatitis therapeutics. She is a member of the Liver Forum. She is also an adviser and consultant to many industries, the U.S. Food and Drug Administration, and biomarker development companies. Dr Abdelmalek advises these groups in the area of diagnostics and therapeutics for metabolic dysfunction-associated steatohepatitis.